Latest news with #JiangsuHengruiPharmaceuticals
Reuters
14 hours ago
- Business
- Reuters
GSK, China's Jiangsu Hengrui strike $500 million drug-development deal
July 28 (Reuters) - Britain's GSK (GSK.L), opens new tab and China's Jiangsu Hengrui Pharmaceuticals ( opens new tab have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition, the drugmakers said on Monday. The deal comes as GSK focuses on growing its pipeline to offset declining revenues from top drugs and vaccines amid slowing demand and rising competition. It is hoping to reach annual sales of over 40 billion pounds ($53.7 billion) by 2031. Under the deal, GSK will gain an exclusive licence to Hengrui's HRS-9821, which is being studied as a treatment for chronic obstructive pulmonary disease, with an option for 11 other treatments once they have cleared early-stage trials. Hengrui said, opens new tab it could earn up to $12 billion in milestone payments if all options are exercised and targets are met under the GSK deal, which would cover therapy areas such as oncology, immunology, and inflammation. GSK will pay the Chinese firm $500 million upfront. "This deal reflects our strategic investment in programmes that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact," GSK Chief Scientific Officer Tony Wood said. Access to HRS-9821 would support GSK's ambition to treat patients across the widest spectrum of chronic obstructive pulmonary disease, the company said, adding that the drug provides an opportunity for a formulation in the form of a convenient, dry-powder inhaler. GSK's existing therapies for COPD include antibody treatment Nucala, opens new tab and the Trelegy Ellipta inhaler. Shanghai-listed shares of Jiangsu Hengrui climbed 6.6% and its Hong Kong-listed stock jumped 8.5%, outperforming the blue-chip CSI 300 Index's (.CSI300), opens new tab 0.1% fall and the Hang Seng Index's (.HIS), opens new tab 0.3% gain. GSK shares were up 1.5% in London by 0830 GMT, against the 0.2% gain in the wider, blue-chip FTSE 100 (.FTSE), opens new tab index. ($1 = 0.7455 pounds)
South China Morning Post
17 hours ago
- Business
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The GSK corporate flag next to a Chinese national flag outside its office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
19 hours ago
- Business
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
Reuters
15-07-2025
- Health
- Reuters
Kailera touts late-stage win for weight-loss drug in China
July 15 (Reuters) - U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' ( opens new tab experimental weight-loss drug has helped overweight patients lose up to 17.7% of body weight in a late-stage study in China, the companies said on Tuesday. Up to 88% of participants who received the drug, known as KAI-9531 outside China, lost at least 5% of their weight after 48 weeks compared to placebo, meeting the study's main goals. The data comes at a time when U.S. drugmakers are increasingly looking to China to secure the rights to promising drug candidates at a lower cost and access important early data that could pave the way for global trials. "As we think about commercial opportunity, this is a really good first look as to what we think we're going to be able to leverage in terms of (obesity treatment) marketplace going forward," Kailera CEO Ron Renaud said. The startup was launched last year with a rare $400 million early-stage funding and four obesity drug candidates licensed from Hengrui, in a move to grab a slice of the obesity treatment market primed to be worth $150 billion by the end of the decade. KAI-9531, administered as a weekly injection, belongs to a the GLP-1 class of treatments that include Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The drugs work by helping control blood sugar levels and triggering a feeling of fullness. "Where we're really focused is where weight loss matters most, which is in people living with higher BMIs (body mass index)," Chief Commercial Officer Jamie Coleman said. "Today's a lot of clinical need on the table for people who need to lose more than 20% (of weight)." In the study that included 567 participants, a six-milligram dose of the drug led to an average weight loss of 17.7% compared to placebo. The companies said the side effects were mild to moderate and gastrointestinal-related, consistent with similar treatments. Hengrui plans to seek regulatory approval in China, while Kailera will pursue global trials with higher doses and extended treatment durations. Earlier this year, an eight-milligram dose of the drug led to an average weight loss of 22.8% in a mid-stage trial.
Bloomberg
23-05-2025
- Business
- Bloomberg
Chinese Firms' Stellar HK Debuts Spur Hopes of Valuation Shift
The robust performance of two major Hong Kong stock listings this week has raised hopes that a small group of elite Chinese companies may start driving a shift to end the city's historical discount to mainland markets. The latest addition to the cohort is Jiangsu Hengrui Pharmaceuticals Co., China's largest drugmaker by market value, which surged as much as 37% in its trading debut Friday in the Asian financial hub after raising HK$9.9 billion ($1.3 billion). The company's H-shares briefly commanded a 0.3% premium over its Shanghai-listed A-shares, before reverting to a discount of 4%.
